Anna Pasieka

Anna Pasieka

Auto-generated profile, based on publicly available information

Anna Pasieka

Department of Physicochemical Drug Analysis Faculty of Pharmacy Jagiellonian University Medical College Medyczna St. 9 30-688 Cracow Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
NSNatalia Szałaj
Natalia Szałaj
JGJustyna Godyń
Justyna Godyń
JJJakub Jończyk
Jakub Jończyk
APAnna Pasieka
Anna Pasieka
DPDawid Panek
Dawid Panek
AWAnna Wieckowska
Anna Wieckowska
Effective therapy of Alzheimer’s disease (AD) requires treatment with a combination of drugs that modulate various pathomechanisms contributing to the disease. In our research, we have focused on the development of multi-target-directed ligands – 5-HT6 receptor antagonists and cholinesterase inhibitors – with disease-modifying properties. We have performed extended in vitro (FRET assay) and in cellulo (Escherichia coli model of protein aggregation) studies on their β-secretase, tau, and amyloid β aggregation inhibitory activity. Within these multifunctional ligands, we have identified compound 17 with inhibitory potency against tau and amyloid β aggregation in in cellulo assay of 59% and 56% at 10 µM, respectively, hBACE IC50=4 µM, h5TH6 Ki=94 nM, hAChE IC50=26 nM, and eqBuChE IC50=5 nM. This study led to the development of multifunctional ligands with a broad range of biological activities crucial not only for the symptomatic but also for the disease-modifying treatment of AD.

22 November 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
DPDawid Panek
Dawid Panek
APAnna Pasieka
Anna Pasieka
JJJakub Jończyk
Jakub Jończyk
MGMilena Gawlińska
Milena Gawlińska
PZPaula Zaręba
Paula Zaręba
Barbara MalawskaBarbara Malawska
Barbara Malawska
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ‐aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC50=0.21 μM) and GABA transporter 1 (IC50=10.96 μM) and 3 (IC50=7.76 μM), along with a favorable drug‐likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi‐target‐directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.

22 November 2024 in Angewandte Chemie
Verified
Journal Article
Open access
DPDawid Panek
Dawid Panek
APAnna Pasieka
Anna Pasieka
JJJakub Jończyk
Jakub Jończyk
MGMilena Gawlińska
Milena Gawlińska
PZPaula Zaręba
Paula Zaręba
Barbara MalawskaBarbara Malawska
Barbara Malawska
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ‐aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC50=0.21 μM) and GABA transporter 1 (IC50=10.96 μM) and 3 (IC50=7.76 μM), along with a favorable drug‐likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi‐target‐directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.